Whereas the ACF cohort had eligibility criteria of baseline CD4 count ≤350 cells/mm3 and/or WHO stage 4, all ART-naïve TB patients irrespective of CD4 count and WHO stage were recruited in the PCF cohort. This evidence concerns the gene CD4 and tuberculosis.